Galen Buckwalter says brain-computer interfaces will have to be enjoyable to use if the technology is going to be successful.
R3 Bio has a bold idea for replacing lab animals: genetically-engineered whole organ systems that lack a brain. The long-term goal, says a cofounder, is to make human versions.
While the United States and Europe are moving cautiously forward with clinical trials, China is racing toward the commercialization of brain implants.
Researchers in Japan pioneered reprogrammed cells 20 years ago. Now the country has given the first-ever authorizations to manufacture and sell medical products based on the technology.
No one has had a Synchron brain-computer interface longer than Rodney Gorham. He’s still finding new ways to use it.
Gestala is the latest company to emerge from China’s burgeoning brain-computer interface industry. It plans to access the brain with noninvasive ultrasound technology.
Chinese scientist He Jiankui wants to end Alzheimer’s and thinks Silicon Valley is conducting a “Nazi eugenic experiment.”
Merge Labs has emerged from stealth with $252 million in funding from OpenAI and others. It aims to use ultrasound to read from and write to the brain.
Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA regulatory pathway to commercialize treatments for rare diseases.
Researchers suggest that they have recovered sequences from ancient works and letters that may belong to the Renaissance genius.